Intestinal ulcers induced by intravesical bacillus Calmette-Guérin therapy

References

• Bernini L, Manzini CU, Giuggioli D, et al. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev. 2013;12(12):1150–1159.
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Yadav PK, Su JL, et al. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009;15(46):5784–5788.
   Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.
   PubMed Web of Science ®Google Scholar
• Hölttä V, Klemetti P, Sipponen T, et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis. 2008;14(9):1175–1184.
   Web of Science ®Google Scholar
• Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14(4):437–445.
   PubMed Web of Science ®Google Scholar
• Jiang W, Su J, Zhang X, et al. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res. 2014;63(11):943–950.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124.
   PubMed Web of Science ®Google Scholar
• MacDonald JK, Nguyen TM, Khanna R, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2016;11(11):CD007572.
   Google Scholar
• Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671–680.
   PubMed Web of Science ®Google Scholar
• Firinu D, Barca MP, Lorrai MM, Perra S, et al. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity. 2014;47(6):389–394.
   PubMed Web of Science ®Google Scholar
• Wendling D, Aubin F, Verhoeven F, et al. IL-23/Th17 targeted therapies in SAPHO syndrome. A case series. Joint Bone Spine. 2017;84(6):733–735.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34(6):1019–1023.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19(1):51.
   PubMedGoogle Scholar
• Thiboutot DM, Layton AM, Anne Eady E. IL-17: a key player in the P. acnes inflammatory cascade? J Invest Dermatol. 2014;134(2):307–310.
   PubMed Web of Science ®Google Scholar
• Kelhälä HL, Palatsi R, Fyhrquist N, et al. IL-17/Th17 pathway is activated in acne lesions. PloS One. 2014;9(8):e105238.
   PubMed Web of Science ®Google Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144.
   PubMed Web of Science ®Google Scholar
• Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845–847.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Fuentes-Duculan J, Mashiko S, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J Dermatol Sci. 2017;85(1):20–26.
   Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.
   PubMed Web of Science ®Google Scholar
• Croes M, Öner FC, van Neerven D, et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone. 2016;84:262–270.
   PubMed Web of Science ®Google Scholar
• Ono T, Okamoto K, Nakashima T, et al. IL-17-producing γδ T cells enhance bone regeneration. Nat Commun. 2016;7:10928.
   PubMed Web of Science ®Google Scholar
• Osta B, Roux JP, Lavocat F, et al. Differential effects of IL-17A and TNF-α on osteoblastic differentiation of isolated synoviocytes and on bone explants from arthritis patients. Front Immunol. 2015;6:151.
   Web of Science ®Google Scholar
• Osta B, Lavocat F, Eljaafari A, et al. Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
   Web of Science ®Google Scholar
• Daoussis D, Konstantopoulou G, Kraniotis P, et al. Biologics in SAPHO syndrome: a systematic review. Semin Arthritis Rheum. 2019;48(4):618–625.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75(2):408–412.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013;382(9906):1705–1713.
   PubMed Web of Science ®Google Scholar
• Cortes A, Hadler J, Pointon JP, Robinson PC, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730–738.
   PubMed Web of Science ®Google Scholar
• Saban MR, Simpson C, Davis C, et al. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol. 2007;8(1):6.
   Google Scholar
• Zuiverloon TC, Nieuweboer AJ, Vékony H, et al. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol. 2012;61(1):128–145.
   PubMed Web of Science ®Google Scholar
• Davalos L, Kushlaf H. New onset of seropositive generalized myasthenia gravis following intravesical bacille Calmette-Guerin treatment for bladder cancer: a case study. Muscle Nerve. 2019;59(1):E1–E2.
   Web of Science ®Google Scholar
• Takizawa T, Kojima M, Suzuki S, et al. New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: a case report and literature review. Medicine (Baltimore)). 2017;96(46):e8757.
   Web of Science ®Google Scholar